Cancer Research UK Laboratories, Department of Oncology, MRC Cyclotron Building, Faculty of Medicine, Imperial College London, Du Cane Road, London W12 ONN, UK.
Nat Rev Clin Oncol. 2010 Oct;7(10):561-74. doi: 10.1038/nrclinonc.2010.122. Epub 2010 Aug 31.
Adjuvant use of anthracycline-taxane combination therapy is an accepted strategy in the management of high-risk early-stage breast cancer. However, the introduction of this regimen raises the question of how best to manage those patients who relapse following adjuvant therapy, and whether there is a role for rechallenging in the metastatic setting with the same agent, or class of agent, that has been utilized in the adjuvant setting. This Review examines the evidence for rechallenging with both anthracyclines and taxanes, and highlights the issues that need to be examined in the context of future clinical trials.
辅助使用蒽环类药物-紫杉烷类联合治疗方案是高危早期乳腺癌治疗管理中的一种公认策略。然而，这种治疗方案的引入提出了一个问题，即如何最好地管理那些在辅助治疗后复发的患者，以及在辅助治疗中使用的同一药物或药物类别是否有在转移性疾病中再次使用的作用。这篇综述探讨了蒽环类药物和紫杉烷类药物再次使用的证据，并强调了在未来临床试验中需要研究的问题。
